Meta-Analysis
Copyright ©The Author(s) 2022.
World J Gastrointest Oncol. Oct 15, 2022; 14(10): 2061-2076
Published online Oct 15, 2022. doi: 10.4251/wjgo.v14.i10.2061
Table 1 Characteristics of trials included in the analysis
Ref.NCT numberCountry/regionsStudy periodNumber of patients
Chemotherapy regimen
CT
CT + TT
Valle et al[1], 2021NCT0271155318 countries and regionsaMay, 2016 to Aug, 2017101106CisGem
102
Vogel et al[17], 2018NCT01320254GermanyJul, 2011 to Dec, 20152862CisGem
Leone et al[18], 2016NCT01389414ItalyJun, 2010 to Sept, 20134445GemOx
Valle et al[19], 2015NCT00939848UKApr, 2011 to Sept, 20126062CisGem
Santoro et al[21], 2015NCT00753675ItalyOct, 2008 to Sept, 20125658Gemcitabine
Chen et al[20], 2015NCT01267344ChinaDec, 2010 to May, 20126062GemOx
Moehler et al[22], 2014NCT00661830GermanyMay, 2008 to Jul, 20114849Gemcitabine
Malka et al[23], 2014NCT00552149France and GermanyOct, 2007 to Dec, 20097476GemOx
Lee et al[24], 2012NCT01149122South KoreaFeb, 2009 to Aug, 2010133135GemOx
Table 2 Patient characteristics in the included studies
Ref.
Design
Age, median
Males/females
ECOG 0/1-2
Locally advanced/metastatic
Primary tumour site
Valle et al[1], 2021CisGem5953/4861/392/98iCCA, 55; GBC, 26; eCCA, 14; AoV, 5
Ramucirumab6446/6045/583/103iCCA, 56; GBC, 24; eCCA, 18; AoV, 8
Merestinib6248/5452/504/98iCCA, 60; GBC, 22; eCCA, 14; AoV, 6
Vogel et al[17], 2018CisGem59.514/1411/175/17GBC, 3; dCCA, 1; pCCA, 2; iCCA, 20; Others, 6
Panitumumab6236/2621/3913/42GBC, 11; dCCA, 7; pCCA, 2; iCCA, 41; Others, 6
Leone et al[18], 2016GemOx64.215/291/436/38iCCA, 21; eCCA, 7; GBC, 16
Panitumumab63.917/280/458/37iCCA, 21; eCCA, 12; GBC, 12
Valle et al[19], 2015CisGem64.528/3428/348/54iCCA, 15; eCCA, 24; GBC, 19; AoV, 4
Cediranib6834/2827/3512/50iCCA, 14; eCCA, 24; GBC, 20; AoV, 4
Santoro et al[21], 2015Gemcitabine6425/3134/21NRiCCA, 29; eCCA, 13; GBC, 7; AoV, 6
Vandetanib64.431/2736/23NRiCCA, 31; eCCA, 10; GBC, 13; AoV, 4
Chen et al[20], 2015GemOx5930/3017/4317/43iCCA, 45; eCCA, 10; GBC, 5
Cetuximab6128/3418/4423/39iCCA, 44; eCCA, 9; GBC, 9;
Moehler et al[22], 2014Gemcitabine64.525/239/35NRGBC, 7; iCCA, 29
Sorafenib6429/2017/30NRGBC, 6; iCCA, 33
Malka et al[23], 2014GemOx6242/3227/4315/59iCCA, 46; eCCA, 14; GBC, 11; AoV, 0
Cetuximab6143/3335/3617/59iCCA, 49; eCCA, 8; GBC, 11; AoV, 1
Lee et al[24], 2012GemOx6179/5420/1130/133CCA, 84; GBC, 47; AoV, 2;
Erlotinib5991/4426/1090/135CCA, 96; GBC, 35; AoV, 4